Clinical and Experimental Allergy最新文献

{"title":"Quality of Life in Paediatric Food Allergy: Diverging Influences on Parent and Child Reports in the ROAD Study.","authors":"Chisato Jimbo, Sayaka Hamaguchi, Kenji Toyokuni, Miori Sato, Ai Kishino, Mami Shimada, Tomoki Yaguchi, Kouhei Hagino, Daisuke Harama, Marei Omori, Daichi Suzuki, Kotaro Umezawa, Fumi Ishikawa, Seiko Hirai, Mayako Saito-Abe, Tatsuki Fukuie, Yukihiro Ohya, Kiwako Yamamoto-Hanada","doi":"10.1111/cea.70143","DOIUrl":"https://doi.org/10.1111/cea.70143","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"British Society for Allergy and Immunology Abstracts From the 2025 Annual Conference.","authors":"","doi":"10.1111/cea.70139","DOIUrl":"https://doi.org/10.1111/cea.70139","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Children Allergic to Peanut and/or Tree Nuts Are at Risk of Accidental Allergic Reactions.","authors":"Marina Vasse, Marie Moyart, Camille Cisterne, Caroline Thumerelle, Elodie Drumez, Hélène Béhal, Guillaume Pouessel, Stéphanie Lejeune, Antoine Deschildre","doi":"10.1111/cea.70132","DOIUrl":"https://doi.org/10.1111/cea.70132","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mass Spectrometry-Based Proteomics Analysis of Nasal Fluid Uncovers Differentially Expressed Proteins as Potential Biomarkers of Allergic Asthma.","authors":"Jamie A Rosado Alicea, Shad Morton, Alyson N Brown, Bogdan Budnik, Ayobami Akenroye, Rushdy Ahmad, Tanya M Laidlaw","doi":"10.1111/cea.70140","DOIUrl":"10.1111/cea.70140","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food Allergy Prevention: Is Earlier Complementary Food Introduction Really the Optimal Approach?","authors":"Catherine Breen, Roberta Scarpone, Michael R. Perkin, Robert J. Boyle","doi":"10.1111/cea.70142","DOIUrl":"10.1111/cea.70142","url":null,"abstract":"<p>It is now widely accepted in the allergy community and wider society that the phenomenon of oral tolerance is relevant to the development of Immunoglobulin-E mediated food allergy in humans. However, the optimal application of oral tolerance for preventing food allergy is unclear. Debate about how to implement oral tolerance for food allergy prevention is currently at risk of pitting public health and allergy communities against each other over the timing of complementary food introduction. In this editorial, we review the evidence for using oral tolerance to prevent food allergy. We highlight limitations of the available data in relation to informing public health guidance for the timing of complementary food introduction. We suggest research is needed to establish whether the optimal approach to food allergy prevention might involve allergenic food introduction that is consistent with current public health guidance.</p><p>Oral tolerance was first described by Harry Gideon Wells over 100 years ago, while studying the development of hen's egg allergy in guinea pigs [<span>1</span>]. Wells noted that if young guinea pigs were fed hen's egg before he started an egg sensitisation protocol, egg allergy could not be induced. In contrast, if the pups were not fed hen's egg before sensitisation began, egg allergy could be induced. Although oral tolerance is now a well-understood feature of immunology research in a range of animal and in vitro models, it took over 100 years from Wells's original observations before we found a successful human application of oral tolerance. That application is the inclusion of allergenic foods in the human diet during infancy, to prevent the development of IgE-mediated food allergy. Like in Wells's guinea pigs, the strongest evidence for oral tolerance in humans is for the prevention of common forms of IgE-mediated food allergy such as egg or peanut allergy [<span>2</span>]. Infant feeding guidelines in many regions of the world now recommend including common allergenic foods such as egg or peanut in the infant diet, rather than avoiding such foods. But important questions remain about optimising allergy prevention using allergenic food introduction.</p><p>In Wells's classic description of oral tolerance, he noted that early, short-term feeding of a food antigen was not sufficient to induce oral tolerance, but prolonged exposure reliably prevented the development of allergy. He stated, ‘Apparently, then, daily absorption of animal protein in the food at first renders guinea-pigs hypersensitive to this protein, but if the feeding is kept up for a long enough period the animals become refractory to the food protein.’ So Wells's work supports the potential relevance of prolonged oral allergen exposure for effective tolerance induction. Timing of allergenic food introduction is also important, because oral tolerance induction is simpler when allergenic foods are introduced before food allergy has developed. However, the re","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"55 9","pages":"748-751"},"PeriodicalIF":5.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the Burden and Risk Factors of Allergic Diseases and Asthma Among Aboriginal and Torres Strait Islander People: A Scoping Review.","authors":"Desalegn Markos Shifti, Erin Pitt, Lesley Versteegh, Rani Scott Farmer, Catherine J Hornung, Victoria Gibson, Diane Maresco-Pennisi, Shyamali C Dharmage, Anne B Chang, Jennifer J Koplin","doi":"10.1111/cea.70138","DOIUrl":"https://doi.org/10.1111/cea.70138","url":null,"abstract":"<p><p>Allergic diseases and asthma are significant public health concerns in Australia and globally. However, comprehensive data on the burden among Aboriginal and Torres Strait Islander people are scarce. This scoping review aimed to systematically map existing evidence on the burden and risk factors of allergic diseases and asthma among Aboriginal and Torres Strait Islander people. MEDLINE, Scopus, Embase and Web of Science Core Collection were systematically searched through March 2024. We included studies that reported allergic diseases and asthma among Aboriginal and Torres Strait Islander people. Study characteristics and outcome data were tabulated and evidence was synthesised narratively. Fifty-four studies involving an estimated 176,792 Aboriginal and Torres Strait Islander people were included. These studies reported on asthma (n = 48), eczema (n = 10), allergic rhinitis (n = 6), atopy (n = 3), mixed allergies (combining food, drug and other undefined allergies) (n = 2), and anaphylaxis (n = 1). No studies solely investigating food allergies were found. The majority of studies were from Western Australia (WA, n = 15) and the Northern Territory (NT, n = 14). Estimates of allergy prevalence varied widely between studies, with eczema ranging from 2.0% to 44.4%, allergic rhinitis from 0.2% to 37.3%, and atopy from 1.7% to 36.4%. Asthma prevalence ranged from 2.0% to 50.5%. Risk factors for asthma included exposure to smoke and lower socioeconomic status, while a family history of allergy was associated with an increased risk of allergic rhinitis. In conclusion, Aboriginal and Torres Strait Islander people face a potentially significant burden of allergic diseases and asthma, yet they remain underrepresented in research. Culturally responsive studies are needed to address this substantial evidence gap.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food Anaphylaxis: Eight Food Allergens Without Mandatory Labelling Highlighted by the French Allergy-Vigilance Network.","authors":"Dominique Sabouraud-Leclerc, Delphine Mariotte, Elena Bradatan, Amandine Divaret-Chauveau, Carine Metz-Favre, Pascale Beaumont, Pascale Dumond, Julien Serrier, Yasemin Karaca-Altintas, Sélina Tscheiller, Guillaume Pouessel, Xavier Van der Brempt","doi":"10.1111/cea.70130","DOIUrl":"10.1111/cea.70130","url":null,"abstract":"<p><strong>Background: </strong>The European Regulation list on mandatory labelling of foods includes 14 allergenic foods; however, other foods are also frequently implicated in food-induced anaphylaxis (FIA).</p><p><strong>Methods: </strong>We analysed FIA cases reported to the Allergy Vigilance Network from 2002 to 2023. Allergenic foods involved in ≥ 1% of cases and not included in the list were assessed as emerging food allergens (EFA). We assessed their frequency, severity (Ring classification), recurrence, and potential presence in hidden form to determine which allergens might warrant inclusion on the list.</p><p><strong>Results: </strong>Among 2999 FIA cases (Ring grades 2-4), 413 cases (13.8%) met the selection criteria, divided into eight allergenic foods or food groups: goat's and sheep's milk (GSM, n = 84; 2.8% of the cases), buckwheat (n = 71; 2.4%), peas and lentil (n = 55; 1.8%), alpha-gal (n = 50; 1.7%), pine nut (n = 49; 1.6%), kiwi (n = 44; 1.5%), beehive products (n = 30; 1.0%), and apple (n = 30; 1.0%). Severe reactions (Ring grades 3 and 4) were reported with GSM (46.8% and 4.8%, respectively, including two fatalities), buckwheat (46.5% and1.4%), peas-lentil (20% and 1.8%), alpha-gal (54% and 8%), and Grade 3 reactions were reported with pine nut in 49%, kiwi 54.5%, beehive products 33.3% and apple 46.7%. Recurrent reactions and hidden exposures were reported with GSM (56% and 15.5%), buckwheat (49.3% and 16.9%), peas-lentil (7.3% and 9.0%) and pine nut (12.2% and 4.1%).</p><p><strong>Conclusion: </strong>We identified eight foods frequently involved in FIA and not currently listed in the European regulation. Given their frequency, severity, recurrence, and potential for hidden exposure, we propose that four-goat's and sheep's milk, buckwheat, peas-lentil, and pine nut-be considered for inclusion in the list.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Topical and Systemic Treatments for Atopic Dermatitis.","authors":"Sara Mirali, Aaron M Drucker","doi":"10.1111/cea.70136","DOIUrl":"https://doi.org/10.1111/cea.70136","url":null,"abstract":"<p><p>Atopic dermatitis is an inflammatory skin condition characterised by pruritus and a chronic relapsing-remitting course. Previous topical and systemic treatments for atopic dermatitis were broadly immunosuppressive, which limited their long-term use. Recently, more targeted therapies for atopic dermatitis have been developed. In this review, we discuss the efficacy and safety of new therapies, including topical PDE4 (phosphodiesterase 4) inhibitors, a topical aryl hydrocarbon receptor agonist, topical and systemic JAK (Janus kinase) inhibitors and biologics.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape of Aeroallergen Sensitization in Asia.","authors":"Xiaoling Yin, Xiangling Zhang, Feng Xu, Hao Xiao, Juan Meng, Philip H Li","doi":"10.1111/cea.70137","DOIUrl":"https://doi.org/10.1111/cea.70137","url":null,"abstract":"<p><p>Allergic diseases caused by aeroallergens are emerging as a critical public health issue across Asia. Diverse climatic and geographic conditions play a significant role in shaping regional variation in aeroallergy sensitisation patterns across Asia. House dust mites (HDMs) remain the predominant indoor allergens, while pollen sensitisation varies substantially based on regional flora. Rapid urbanisation, evolving lifestyles, increasing air pollution, and genetic susceptibility further influence allergen exposure and sensitisation profiles. Although pharmacological and biologic therapies have advanced, allergen-specific immunotherapy (AIT) remains the only disease-modifying therapeutic strategy. This review synthesises current evidence on aeroallergen sensitisation patterns across Asia, elucidates key influencing factors across various Asian regions, and discusses current prevention and treatment strategies, emphasising the role and challenges of AIT. Improved understanding of these regional allergenic profiles and management practices is essential for developing tailored clinical guidelines and public health interventions.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral Peanut Immunotherapy With Butyrate Adjuvant (OPIA) in Children: A Randomised, Controlled Trial.","authors":"Peter S Hsu, Elizabeth H Barnes, Michelle Barnes, Merilyn McArthur, Carolina Valerio, Brigitte Santner-Nanan, Gabriela Pinget, Yanan Wang, Cuong D Tran, Catherine L Lai, Isabelle M L Bosi, Tennille L Vitagliano, Laurence Macia, David McDonald, Nanju Alice Lee, Sam Mehr, Paul J Turner, Julie M Clarke, Dianne E Campbell, Ralph Nanan","doi":"10.1111/cea.70127","DOIUrl":"https://doi.org/10.1111/cea.70127","url":null,"abstract":"<p><strong>Background: </strong>Sustained unresponsiveness (SU) remains a major challenge for peanut OIT. The short chain fatty acid (SCFA) butyrate has the potential to upregulate regulatory T cells (Tregs) to improve long term tolerance. We conducted a superiority randomised controlled trial to assess the efficacy and safety of the addition of daily oral butyrate to peanut OIT.</p><p><strong>Methods: </strong>Peanut allergic children (aged 10-16 years) were recruited in a single-centre randomised double-blind placebo-controlled trial and randomised 2:2:1 to receive 12 months daily peanut OIT with HAMSB (OIT + butyrate), peanut OIT with LAMS (OIT + placebo) or no OIT (control) following an entry DBPCFC. Allocation of HAMSB and LAMS was blinded. Peanut OIT was open. Exit DBPCFC was performed after at least 6 weeks of treatment cessation. The primary outcome was the proportion of participants who tolerated ≥ 1000 mg of peanut protein (cumulative dose 1449 mg) at exit DBPCFC. Adverse events and compliance were recorded. Blood Treg responses and stool SCFA analysis were performed.</p><p><strong>Results: </strong>A total of 65 participants were enrolled (male 57%, median age 12 years). Of these 26 participants received OIT + butyrate, 26 received OIT + placebo, and 13 received standard care with no OIT (control). After 6 weeks of treatment cessation, 73% (19/26) of OIT + butyrate, 69% (18/26) of OIT + placebo (OR 95% CI = 1.21 (0.36-4.0) for OIT + butyrate relative to OIT + placebo, p = 0.76) and 0% (0/13) of the control group tolerated at least 1000 mg (cumulative dose 1449 mg) of peanut protein. The most common adverse events observed in OIT + butyrate and OIT + placebo were gastrointestinal related (73%). Treatment-related anaphylaxis occurred in eight participants; four in each OIT group (15%). There was no statistically significant difference in AE rate between OIT + butyrate and OIT + placebo.</p><p><strong>Interpretation: </strong>In a first in food allergy clinical trial setting, the addition of oral butyrate to peanut OIT was well tolerated but did not enhance SU rate in our cohort.</p><p><strong>Trial registration: </strong>Australian New Zealand Clinical Trials Registry (ANZCTR) - ACTRN12617000914369; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617000914369; Trial was registered on 22 June 2017.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144844727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}